201 related articles for article (PubMed ID: 32675056)
21. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
[TBL] [Abstract][Full Text] [Related]
22. Survival Analysis of Cancer Patients With FIGO Stage IIIA Endometrial Cancer.
Lum MM; Belnap TW; Frandsen J; Brown AP; Sause WT; Soisson AP; Dodson MK; Werner T; Gaffney DK
Am J Clin Oncol; 2015 Jun; 38(3):283-8. PubMed ID: 23774072
[TBL] [Abstract][Full Text] [Related]
23. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy.
Mehta N; Yamada SD; Rotmensch J; Mundt AJ
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1004-9. PubMed ID: 14575831
[TBL] [Abstract][Full Text] [Related]
24. The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis.
Qu XM; Velker VM; Leung E; Kwon JS; Elshaikh MA; Kong I; Logie NA; Mendez LC; van der Putten LJ; Donovan EK; Munkarah AR; Wiebe EM; Parra-Herran C; Warner A; Louie AV; D'Souza DP
Gynecol Oncol; 2018 May; 149(2):283-290. PubMed ID: 29544706
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of sentinel lymph node mapping for patients with FIGO stage I endometrioid endometrial carcinoma.
Nasioudis D; Byrne M; Ko EM; Giuntoli RL; Haggerty AF; Cory L; Kim SH; Morgan MA; Latif NA
Gynecol Oncol; 2021 Jun; 161(3):705-709. PubMed ID: 33771397
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma.
Nagar H; Yan W; Parashar B; Nori D; Chao KS; Christos P; Gupta D; Holcomb K; Caputo T; Wernicke AG
Am J Clin Oncol; 2016 Aug; 39(4):335-9. PubMed ID: 27028349
[TBL] [Abstract][Full Text] [Related]
27. Extrauterine Spread, Adjuvant Treatment, and Prognosis in Noninvasive Uterine Papillary Serous Carcinoma of the Endometrium: A Retrospective Multicenter Study.
Boyraz G; Salman MC; Basaran D; Ozgul N; Turan T; Turkmen O; Kimyon GC; Ozkan NT; Cagan M; Gungor T; Meydanli MM; Gungorduk K; Gulseren V; Sanci M; Yuce K
Int J Gynecol Cancer; 2017 Jan; 27(1):102-108. PubMed ID: 27668395
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of minimally invasive surgery for patients with endometrial carcinoma involving the cervix.
Nasioudis D; Frey MK; Chapman-Davis E; Caputo TA; Holcomb K
Int J Gynecol Cancer; 2020 May; 30(5):619-625. PubMed ID: 32276935
[TBL] [Abstract][Full Text] [Related]
29. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
[TBL] [Abstract][Full Text] [Related]
30. National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma.
Xiang M; English DP; Kidd EA
Gynecol Oncol; 2019 Mar; 152(3):599-604. PubMed ID: 30551884
[TBL] [Abstract][Full Text] [Related]
31. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.
Murphy KT; Rotmensch J; Yamada SD; Mundt AJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1272-6. PubMed ID: 12654437
[TBL] [Abstract][Full Text] [Related]
32. Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data Base.
Lester-Coll NH; Park HS; Rutter CE; Corso CD; Young MR; Ratner ES; Litkouhi B; Decker RH; Yu JB; Damast S
Gynecol Oncol; 2016 Jul; 142(1):54-61. PubMed ID: 27151429
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.
Kuku S; Williams M; McCormack M
Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study.
Mahdi H; Rose PG; Elshaikh MA; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; DeBenardo R
Gynecol Oncol; 2015 Mar; 136(3):529-33. PubMed ID: 25575483
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant radiation followed by chemotherapy is associated with improved overall survival in endometrial cancer.
Sinha S; Lazar A; Lam A; Anderson EM; Chen LM; Hsu IJ; Yoshida EJ
Gynecol Oncol; 2020 Oct; 159(1):30-35. PubMed ID: 32811681
[TBL] [Abstract][Full Text] [Related]
36. Is there a benefit of performing an omentectomy for clinical stage I high-grade endometrial carcinoma?
Nasioudis D; Heyward Q; Gysler S; Giuntoli RL; Cory L; Kim S; Morgan MA; Haggerty AF; Ko EM; Latif NA
Surg Oncol; 2021 Jun; 37():101534. PubMed ID: 33667893
[TBL] [Abstract][Full Text] [Related]
37. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study.
van Weelden WJ; Reijnen C; Eggink FA; Boll D; Ottevanger PB; van den Berg HA; van der Aa MA; Pijnenborg JMA
Eur J Cancer; 2020 Jul; 133():104-111. PubMed ID: 32454416
[TBL] [Abstract][Full Text] [Related]
38. Analysis of FIGO Stage IIIc endometrial cancer patients.
McMeekin DS; Lashbrook D; Gold M; Johnson G; Walker JL; Mannel R
Gynecol Oncol; 2001 May; 81(2):273-8. PubMed ID: 11330962
[TBL] [Abstract][Full Text] [Related]
39. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy.
Nelson G; Randall M; Sutton G; Moore D; Hurteau J; Look K
Gynecol Oncol; 1999 Nov; 75(2):211-4. PubMed ID: 10525373
[TBL] [Abstract][Full Text] [Related]
40. Radical hysterectomy is not associated with a survival benefit for patients with stage II endometrial carcinoma.
Nasioudis D; Sakamuri S; Ko EM; Haggerty AF; Giuntoli RL; Burger RA; Morgan MA; Latif NA
Gynecol Oncol; 2020 May; 157(2):335-339. PubMed ID: 32089334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
